Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.
Colloids Surf B Biointerfaces. 2024 Oct;242:114112. doi: 10.1016/j.colsurfb.2024.114112. Epub 2024 Jul 20.
Allergic rhinitis (AR) is a chronic inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE) after exposure to allergens. The bothersome symptoms of AR, such as runny nose and nasal congestion, affect millions of people worldwide. Ipratropium Bromide (IB), commonly used in clinical practice for treating AR, requires frequent administration through nasal spray and may cause significant irritation to the nasal mucosa. The induction of ROS is closely related to the initiation and symptoms of AR, and ROS will continue to accumulate during the onset of AR. To address these challenges, we have designed a drug delivery system that can be administered in liquid form and rapidly crosslink into a ROS-responsive gel in the nasal cavity. This system enables sustained ROS responsive release of IB in a high-concentration ROS environment at AR lesions, thereby alleviating AR symptoms. The gel demonstrated prolonged release of IB for up to 24 hours in rats. In the treatment of AR rat models, it improved their symptoms, reduced the expression of various inflammatory factors, suppressed MUC5AC protein expression, and decreased mucus secretion through a ROS responsive IB release pattern. Overall, this system holds promise as a better option for AR treatment and may inspire the design of nanogel-based nasal drug delivery systems.
变应性鼻炎（AR）是一种由免疫球蛋白 E（IgE）介导的鼻黏膜慢性炎症性疾病，在接触过敏原后发生。AR 的烦人的症状，如流鼻涕和鼻塞，影响着全世界数百万人。异丙托溴铵（IB）是临床常用的治疗 AR 的药物，需要通过鼻喷频繁给药，可能会对鼻黏膜造成明显刺激。ROS 的诱导与 AR 的发病和症状密切相关，ROS 在 AR 发病期间会持续积累。为了解决这些挑战，我们设计了一种药物递送系统，可以以液体形式给药，并在鼻腔中迅速交联成 ROS 响应性凝胶。该系统可使 IB 在 AR 病变处的高浓度 ROS 环境中持续释放 ROS 响应性，从而缓解 AR 症状。该凝胶在大鼠中显示出长达 24 小时的 IB 延长释放。在治疗 AR 大鼠模型中，它改善了它们的症状，通过 ROS 响应性 IB 释放模式减少了各种炎症因子的表达，抑制了 MUC5AC 蛋白的表达，并减少了粘液分泌。总的来说，该系统有望成为治疗 AR 的更好选择，并可能激发基于纳米凝胶的鼻内药物递送系统的设计。
